FeesSafety
Pluang+

Law firm investigates Omeros after stock drops on negative EMA drug approval opinions

Market News
28 Oct 2026, 01:16 WIB
GlobeNewsWire
View Source
Bearish
Law firm investigates Omeros after stock drops on negative EMA drug approval opinions

Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following two significant stock price drops after the European Medicines Agency (EMA) issued negative opinions on Omeros's drug narsoplimab for treating TA-TMA. The stock fell nearly 20% in June and about 14% in October after the EMA's Committee for Medicinal Products for Human Use (CHMP) rejected the marketing authorization application twice. This investigation could impact investor confidence and legal outcomes for Omeros. Investors are advised to contact Pomerantz LLP for claims related to this matter.

Omeros Corporation faces a legal investigation following significant stock price drops tied to regulatory setbacks. For readers following the health sector, here is Pluang's market snapshot as of Oct 28, 2026 05:02 WIB: out of 150 priced health-sector US stocks, 90 rose and 60 fell. Notable movers include SELLAS Life Sciences Group Inc. (SLS) with a 7.32% gain at USD 12.17 and 10X Genomics Inc (TXG) up 6.92% at USD 78.01, despite a high sell order activity of 82%. Novavax Inc (NVAX) also gained 6.70% at USD 10.03 with a majority buy order activity of 74%.

More News

A Race Against Blindness relaunches holiday fundraiser with $125K family prize package including Toyota Sienna and Disney vacation

A Race Against Blindness relaunches holiday fundraiser with $125K family prize package including Toyota Sienna and Disney vacation

A Race Against Blindness has brought back its popular Miles, Magic & Mochas holiday fundraiser, offering supporters a chance to win a prize package valued at $125,000. The package includes a 2026 Toyota Sienna Platinum, a $20,000 Disney vacation awar...

Neutral
25 minutes ago
Shell buys back over 2 million shares as part of its ongoing repurchase program.

Shell buys back over 2 million shares as part of its ongoing repurchase program.

On November 18, 2026, Shell plc repurchased a total of approximately 2.15 million shares across multiple trading venues including the London Stock Exchange and European markets. These shares are being bought back for cancellation under Shell's existi...

Company Fundamentals
Neutral
31 minutes ago
MercadoLibre and Amazon show strong long-term growth despite short-term profit challenges.

MercadoLibre and Amazon show strong long-term growth despite short-term profit challenges.

MercadoLibre and Amazon have both delivered impressive returns over the past decade by continuously growing their customer base, revenue, and profits. MercadoLibre is deliberately sacrificing short-term profits to invest in long-term growth, expandin...

Market News
Bullish
40 minutes ago
Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite potential challenges ahead.

Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite potential challenges ahead.

Pfizer will pay its 352nd consecutive quarterly dividend on December 7, 2026, maintaining a strong track record for investors. The company faces challenges like a patent cliff, costly acquisitions, and clinical setbacks that could threaten this strea...

Company Fundamentals
Neutral
41 minutes ago
General Mills and Realty Income offer high dividend yields as their stock prices near 52-week lows.

General Mills and Realty Income offer high dividend yields as their stock prices near 52-week lows.

General Mills and Realty Income are trading near their 52-week lows, presenting attractive dividend yields of about 7% and 5.7% respectively. General Mills has a strong dividend history of 127 years and covers its dividend with free cash flow despite...

Market News
Bullish
50 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App